北美抗菌药敏测试市场 – 行业趋势和 2030 年预测

北美抗菌药敏测试市场分析及规模

北美抗菌药敏测试 (AST) 市场继续展现出强劲的增长前景，这得益于该地区抗生素耐药性感染的日益流行。人们越来越意识到准确的药敏测试对于指导有效的抗生素治疗和对抗抗菌素耐药性的重要性，这是市场扩张的关键催化剂。AST 方法的技术进步和自动化系统的集成提高了测试效率和准确性。

Data Bridge Market Research 分析，北美抗菌药敏测试市场在 2022 年为 18.1488 亿美元，预计到 2030 年将达到 28.278 亿美元，预计在预测期内的复合年增长率为 5.70%。由于对抗菌测试仪器的需求不断增长，“仪器”在抗菌药敏测试市场的产品类型细分中占据主导地位。除了对市场价值、增长率、细分、地理覆盖范围和主要参与者等市场情景的洞察外，Data Bridge Market Research 整理的市场报告还包括深度专家分析、患者流行病学、渠道分析、定价分析和监管框架。

北美抗菌敏感性测试市场范围和细分

Market Definition

Antimicrobial susceptibility testing (AST) is a laboratory procedure which is used to determine which antimicrobial impedes the growth of bacteria, fungi, and other microorganism causing a specific infection. Susceptibility testing is performed on microorganisms such as bacteria, fungi causing the infection after they have been recovered in a culture of the specimen.

Antibacterial drugs are playing the important role in the prevention of infectious diseases, however, the cases of drug misuse and overuse, led to the development of drug resistance. Delay in diagnosing the harmful microbes makes it difficult to control the spread of infectious diseases. This is putting pressure on the key players to manufacture the test kits which gives accurate and effective results to better treat the patients.            

North America Antimicrobial Susceptibility Testing Market Dynamics

Drivers

• Rising Antibiotic Resistance

Increasing prevalence of antibiotic-resistant bacterial infections necessitates accurate antimicrobial susceptibility testing to guide effective antibiotic treatment. The growing concern about antimicrobial resistance is a significant driver for the market as healthcare providers seek better diagnostic tools to combat this global health threat.

• Technological Advancements in Antimicrobial Susceptibility Testing

Ongoing advancements in AST technologies, including automated systems, molecular diagnostics, and faster testing methods, enhance the efficiency and accuracy of susceptibility testing. These innovations drive market growth as healthcare facilities seek more precise and timely results.

• Demand for Infection Control

The COVID-19 pandemic has highlighted the importance of robust diagnostic capabilities and infection control measures. Healthcare facilities are investing in AST solutions to improve their diagnostic infrastructure, as infections become a major focus for public health.

• Growing Investment for Healthcare Facilities

Surging focus towards improving the condition of healthcare facilities and improving the overall healthcare infrastructure another important factor fostering the growth of the market. Rising number of partnerships and strategic collaborations between the public and private players pertaining to funding and application of new and improved technology is further creating lucrative market opportunities.  

Opportunities

• Rising Demand for Research and Development

Continued investment in research and development can lead to the creation of novel susceptibility testing techniques and the discovery of new biomarkers. Innovations in testing methods, such as genotypic and phenotypic assays, can open new avenues for personalized and precision medicine, creating opportunities for companies to develop and commercialize these cutting-edge technologies.

• Telemedicine and Remote Consultations

The rise of telemedicine and remote consultations offers an opportunity for companies to develop AST solutions that can integrate seamlessly with virtual healthcare platforms. These solutions can enable healthcare providers to discuss test results and treatment options remotely, improving patient access to care and convenience.

Restraints/ Challenges

• High Cost of Antimicrobial Susceptibility Testing

The initial investment and ongoing operational costs associated with advanced AST technologies can be prohibitive for some healthcare facilities, particularly smaller or resource-constrained settings. High costs can limit the adoption of these technologies and restrict market growth.

• Limited Healthcare Infrastructure in Underserved Areas

In some rural or underserved areas, healthcare facilities may lack the infrastructure and resources needed for advanced antimicrobial susceptibility testing. This limitation can hinder market penetration and equitable access to advanced diagnostic tools.

• Data Integration and Interoperability

The integration of AST data into electronic health records (EHRs) and healthcare information systems can be a challenge. Ensuring that the results of susceptibility testing are easily accessible to healthcare providers and that different AST systems can communicate with EHRs is crucial for streamlined patient care.

• Laboratory Capacity and Workforce

There is a shortage of skilled laboratory professionals capable of conducting AST and interpreting results accurately. The demand for susceptibility testing is increasing, and healthcare facilities may struggle to find and retain qualified staff to meet this demand. This challenge can lead to delays in test processing and result reporting.

本抗菌药敏测试市场报告详细介绍了最新发展、贸易法规、进出口分析、生产分析、价值链优化、市场份额、国内和本地市场参与者的影响，分析了新兴收入领域的机会、市场法规的变化、战略市场增长分析、市场规模、类别市场增长、应用领域和主导地位、产品批准、产品发布、地域扩展、市场技术创新。如需了解有关抗菌药敏测试市场的更多信息，请联系 Data Bridge Market Research 获取分析师简报，我们的团队将帮助您做出明智的市场决策，实现市场增长。

最新动态

• 2022 年 5 月，Qualigen Therapeutics 宣布 NanoSynex Ltd（Qualigen 最近与其达成最终协议以收购其多数股权）将在 BioMed Israel 上亮相。NanoSynex 的创新技术致力于将抗菌药敏试验结果的生成时间缩短六倍
• 2022 年 4 月，COPAN Diagnostics 在第 32 届欧洲临床微生物学和传染病大会 (ECCMID 2022) 上展示了其用于临床微生物学鉴定和抗菌药敏试验 (AST) 的一系列全自动解决方案。COPAN 展示了经食品和药物管理局批准的 Colibri，这是一款全自动标本检查仪器，旨在准备 MALDI-TOF ID 目标并为 AST 创建细菌悬浮液

北美抗菌药敏测试市场范围

抗菌敏感性测试市场根据产品类型、方法、类型、应用、最终用户和分销渠道进行细分。这些细分市场之间的增长将帮助您分析行业中增长缓慢的细分市场，并为用户提供有价值的市场概览和市场洞察，帮助他们做出战略决策，确定核心市场应用。

产品类型

• 仪器
• 耗材及配件
• 服务和软件

方法       

• 质谱法
• 稀释
• 纸片扩散法
• 电子测试、基因型方法
• 其他的

类型

• 抗菌测试
• 抗真菌测试
• 其他的

应用

• 临床诊断
• 药物研发
• 流行病学
• 其他的

终端用户

• 医院
• 制药和生物技术公司
• 诊断实验室
• 合同研究组织
• 研究中心和学术机构
• 其他的

分销渠道

• 直销
• 零售销售
• 第三方分销商

抗菌敏感性测试市场区域分析/见解

对抗菌敏感性测试市场进行了分析，并按上述产品类型、方法、类型、应用、最终用户和分销渠道提供了市场规模洞察和趋势。

抗菌敏感性测试市场报告涵盖的国家包括北美的美国、加拿大和墨西哥。

由于流行病和大流行病事件的增加以及医疗保健基础设施的完善，美国在北美市场占据主导地位。

报告的国家部分还提供了影响单个市场因素和国内市场监管变化，这些因素和变化会影响市场的当前和未来趋势。下游和上游价值链分析、技术趋势和波特五力分析、案例研究等数据点是用于预测单个国家市场情景的一些指标。此外，在提供国家数据的预测分析时，还考虑了全球品牌的存在和可用性以及它们因来自本地和国内品牌的大量或稀缺竞争而面临的挑战、国内关税和贸易路线的影响。   

竞争格局和北美抗菌药敏测试市场份额分析

抗菌敏感性测试市场竞争格局提供了按竞争对手划分的详细信息。详细信息包括公司概况、公司财务状况、产生的收入、市场潜力、研发投资、新市场计划、全球影响力、生产基地和设施、生产能力、公司优势和劣势、产品发布、产品宽度和广度、应用主导地位。以上提供的数据点仅与公司对抗菌敏感性测试市场的关注有关。

抗菌敏感性测试市场的一些主要参与者包括：

• BD（美国）
• Synbiosis（英国）
• 珠海迪莱生物科技有限公司 (中国)
• Mast Group Ltd.（英国）
• HiMedia 实验室（印度）
• 赛默飞世尔科技公司（美国）
• Bio-Rad Laboratories, Inc.（美国）
• Creative Diagnostics（美国）
• Genefluidics, Inc.（美国）
• Rosco Diagnostica A/S（丹麦）
• ERBA 集团（印度）
• Liofilchem Srl（意大利）
• Alifax Srl（德国）
• MERLIN Gesellschaft für mikrobiologische Diagnostika mbH（德国）
• 生物梅里埃公司（法国）
• 默克集团（德国）
• 丹纳赫（美国）
• Accelerate Diagnostics, Inc.（美国）
• NuMedii, Inc.（美国）
• BacterioScan, Inc.（美国）

SKU-25670